Biosimilars for Oncologists: what you need to know

Abstract Book


A Clinician´s Guide to Biosimilars in Oncology: Understanding the Science of Extrapolation and Interchangeability 
Elena Wolff-Holz, MD
Paul-Ehrlich Institute, Germany
Chair of the European Medicines Agency’s Biosimilar Medicinal Products
Working Party (BMWP)
Member of the Oncology Working Party (OWP)
Alternate member of the Scientific Advice Working Party (SAWP)


Biosimilars — Can the dream of affordable cancer care come true?
Paul Cornes, MD, B, BM, BCH, MA, MRCP, FRCR
Consultant Clinical Oncologist
Comparative Outcomes Group
Bristol, United Kingdom


Biosimilars: what oncologists need to know
Fernando de Mora Perez, PhD, MBA, from the Autonomous University of Barcelona, Barcelona, Spain, tells us why oncologists need further education on biosimilars. He discusses the reasons why they should be confident that these medicines will be just as safe and effective as the originator brands.  This video was recorded at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain.

Video published with permission from The Video Journal of Oncology –

In the context of the ESMO 2017 industry satellite symposium: Biosimilars for Oncologists:  what you need to know, Fernando de Mora, Professor of Pharmacology – Autonomous University of Barcelona, is interviewed by Suzette Kox, Senior Director International – Biosimilar Medicines Group